Report copyright - PharmaEngine, Inc....2016/09/09 · Novartis JAK1/JAK2 inhibitor Phase 3, Rux + capecitabine vs. capecitabine (JANUS 1) 2 line, n = 318, CRP-high No sufficient level of efficacy in
Please pass captcha verification before submit form